secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-10-14T11:30:05+00:00
Accession:  0001193125-26-421025
Event type: debt
Sentiment:  negative
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Karyopharm extends indenture forbearance period to Oct 22, 2026 from Oct 15
---------------------------------------------------------------------------

- Company extended the end of its Forbearance Period from 11:59 p.m. ET Oct 15, 2026 to 11:59 p.m. ET Oct 22, 2026, absent earlier termination.
- Extension made under Section 19 of the Forbearance Agreement and Limited Waiver to Indentures dated Sept 10, 2026, disclosed in a Sept 11, 2026 Form 8-K.
- Filing does not specify note principal amounts, interest rates, or the underlying covenant defaults prompting forbearance.
- Signed Oct 14, 2026 by Michael Mano, Executive Vice President, Chief Legal Officer and Secretary; KPTI trades on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526421025/0001193125-26-421025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526421025/d451522d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-421025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer